202 related articles for article (PubMed ID: 36914088)
21. B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies.
Pulvirenti F; Fernandez Salinas A; Milito C; Terreri S; Piano Mortari E; Quintarelli C; Di Cecca S; Lagnese G; Punziano A; Guercio M; Bonanni L; Auria S; Villani F; Albano C; Locatelli F; Spadaro G; Carsetti R; Quinti I
Cells; 2021 Oct; 10(11):. PubMed ID: 34831138
[TBL] [Abstract][Full Text] [Related]
22. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
23. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
24. Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19.
Fhied CL; Tarhoni I; Gerard D; Lewin GM; Moudgalya H; Schneider JR; Borgia JA
J Vis Exp; 2022 Feb; (180):. PubMed ID: 35253789
[TBL] [Abstract][Full Text] [Related]
25. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study.
Selma-Royo M; Bäuerl C; Mena-Tudela D; Aguilar-Camprubí L; Pérez-Cano FJ; Parra-Llorca A; Lerin C; Martínez-Costa C; Collado MC
Genome Med; 2022 Apr; 14(1):42. PubMed ID: 35449030
[TBL] [Abstract][Full Text] [Related]
26. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.
Semmler G; Traugott MT; Graninger M; Hoepler W; Seitz T; Kelani H; Karolyi M; Pawelka E; Aragón de La Cruz S; Puchhammer-Stöckl E; Aberle SW; Stiasny K; Zoufaly A; Aberle JH; Weseslindtner L
J Clin Microbiol; 2021 Apr; 59(5):. PubMed ID: 33602698
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study.
Guo Q; Yang L; Peng R; Gao T; Chu X; Jiang D; Ke D; Ren H
Front Public Health; 2022; 10():1067342. PubMed ID: 36620297
[TBL] [Abstract][Full Text] [Related]
29. A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination.
Du J; Zhang D; Pathakamuri JA; Kuebler D; Yang Y; Loginova Y; Chu E; Madej R; Neves JV; Singer B; Radke H; Spencer N; Rizk E; Zhang A; Lu CM; Sha MY
Emerg Microbes Infect; 2022 Dec; 11(1):250-259. PubMed ID: 34951566
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections.
Huber T; Steininger P; Irrgang P; Korn K; Tenbusch M; Diesch K; Achenbach S; Kremer AE; Werblow M; Vetter M; Bogdan C; Held J
Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1983-1997. PubMed ID: 34109500
[TBL] [Abstract][Full Text] [Related]
31. Optimisation and Validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 Spike, RBD, and Nucleoprotein IgG, IgM, and IgA antibodies in Uganda.
Oluka GK; Namubiru P; Kato L; Ankunda V; Gombe B; Cotten M; ; Musenero M; Kaleebu P; Fox J; Serwanga J
Front Immunol; 2023; 14():1113194. PubMed ID: 36999017
[TBL] [Abstract][Full Text] [Related]
32. COVID-19 Alpha Variant (B.1.1.7): Humoral, memory B and T cells in COVID-19 pediatric convalescents.
Gurevich M; Zilkha-Falb R; Sonis P; Magalashvili D; Dolev M; Mandel M; Menascu S; Achiron A
Pediatr Allergy Immunol; 2022 Oct; 33(10):e13863. PubMed ID: 36282137
[TBL] [Abstract][Full Text] [Related]
33. Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring.
Moeller ME; Engsig FN; Bade M; Fock J; Pah P; Soerensen AL; Bang D; Donolato M; Benfield T
Microbiol Spectr; 2022 Apr; 10(2):e0039622. PubMed ID: 35357223
[TBL] [Abstract][Full Text] [Related]
34. Functional Profiling of In Vitro Reactivated Memory B Cells Following Natural SARS-CoV-2 Infection and Gam-COVID-Vac Vaccination.
Astakhova EA; Byazrova MG; Yusubalieva GM; Kulemzin SV; Kruglova NA; Prilipov AG; Baklaushev VP; Gorchakov AA; Taranin AV; Filatov AV
Cells; 2022 Jun; 11(13):. PubMed ID: 35805076
[TBL] [Abstract][Full Text] [Related]
35. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients.
Chansaenroj J; Yorsaeng R; Puenpa J; Wanlapakorn N; Chirathaworn C; Sudhinaraset N; Sripramote M; Chalongviriyalert P; Jirajariyavej S; Kiatpanabhikul P; Saiyarin J; Soudon C; Thienfaidee O; Ayuthaya TPN; Brukesawan C; Intharasongkroh D; Chaiwanichsiri D; Issarasongkhram M; Kitphati R; Mungaomklang A; Thitithanyanont A; Nagavajara P; Poovorawan Y
PLoS One; 2022; 17(4):e0267102. PubMed ID: 35446889
[TBL] [Abstract][Full Text] [Related]
36. A new multiplex SARS-CoV-2 antigen microarray showed correlation of IgG, IgA, and IgM antibodies from patients with COVID-19 disease severity and maintenance of relative IgA and IgM antigen binding over time.
Berre ML; Paulovčáková T; Verissimo CM; Doyle S; Dalton JP; Masterson C; Martínez ER; Walsh L; Gormley C; Laffey JG; McNicholas B; Simpkin AJ; Kilcoyne M
PLoS One; 2023; 18(3):e0283537. PubMed ID: 36996259
[TBL] [Abstract][Full Text] [Related]
37. Infection with SARS-CoV-2 primes immunological memory in human nasal-associated lymphoid tissue.
Mahallawi WH; Aljeraisi TM
Clin Immunol; 2021 Oct; 231():108850. PubMed ID: 34506944
[TBL] [Abstract][Full Text] [Related]
38. SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response.
Takamatsu Y; Omata K; Shimizu Y; Kinoshita-Iwamoto N; Terada M; Suzuki T; Morioka S; Uemura Y; Ohmagari N; Maeda K; Mitsuya H
Microbiol Spectr; 2022 Dec; 10(6):e0271622. PubMed ID: 36219096
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2-specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies.
Jeffery-Smith A; Burton AR; Lens S; Rees-Spear C; Davies J; Patel M; Gopal R; Muir L; Aiano F; Doores KJ; Chow JY; Ladhani SN; Zambon M; McCoy LE; Maini MK
J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 34843448
[TBL] [Abstract][Full Text] [Related]
40. High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines.
Pape KA; Dileepan T; Kabage AJ; Kozysa D; Batres R; Evert C; Matson M; Lopez S; Krueger PD; Graiziger C; Vaughn BP; Shmidt E; Rhein J; Schacker TW; Khoruts A; Jenkins MK
Cell Rep; 2021 Oct; 37(2):109823. PubMed ID: 34610291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
